Arrhythmic risk prediction in arrhythmogenic right ventricular cardiomyopathy: external validation of the arrhythmogenic right ventricular cardiomyopathy risk calculator . (29th June 2022)

• Record Type: Journal Article
• Authors: Jordà, Paloma; Bosman, Laurens P; Gasperetti, Alessio; Mazzanti, Andrea; Gourraud, Jean Baptiste; Davies, Brianna; Frederiksen, Tanja Charlotte; Weidmann, Zoraida Moreno; Di Marco, Andrea; Roberts, Jason D; MacIntyre, Ciorsti; Seifer, Colette; Delinière, Antoine; Alqarawi, Wael; Kukavica, Deni; Minois, Damien; Trancuccio, Alessandro; Arnaud, Marine; Targetti, Mattia; Martino, Annamaria; Oliviero, Giada; Pipilas, Daniel C; Carbucicchio, Corrado; Compagnucci, Paolo; Dello Russo, Antonio; Olivotto, Iacopo; Calò, Leonardo; Lubitz, Steven A; Cutler, Michael J; Chevalier, Philippe; Arbelo, Elena; Priori, Silvia Giuliana; Healey, Jeffrey S; Calkins, Hugh; Casella, Michela; Jensen, Henrik Kjærulf; Tondo, Claudio; Tadros, Rafik; James, Cynthia A; Krahn, Andrew D; Cadrin-Tourigny, Julia;
• Is Part Of: European heart journal. Volume 43:Number 32(2022)
• Page Start: 3041
• Page End: 3052
• Publication Date: 2022-06-29
• Subjects: Arrhythmogenic right ventricular cardiomyopathy -- Implantable cardioverter-defibrillator -- Sudden cardiac death -- Ventricular arrhythmias -- Risk stratification -- Genetic cardiomyopathies; Cardiology -- Periodicals; Heart -- Diseases -- Periodicals; 616.12005
• DOI: 10.1093/eurheartj/ehac289
• Languages: English
• ISSNs: 0195-668X

Abstract

Abstract: Aims: Arrhythmogenic right ventricular cardiomyopathy (ARVC) causes ventricular arrhythmias (VAs) and sudden cardiac death (SCD). In 2019, a risk prediction model that estimates the 5-year risk of incident VAs in ARVC was developed (ARVCrisk.com). This study aimed to externally validate this prediction model in a large international multicentre cohort and to compare its performance with the risk factor approach recommended for implantable cardioverter-defibrillator (ICD) use by published guidelines and expert consensus. Methods and results: In a retrospective cohort of 429 individuals from 29 centres in North America and Europe, 103 (24%) experienced sustained VA during a median follow-up of 5.02 (2.05–7.90) years following diagnosis of ARVC. External validation yielded good discrimination [C-index of 0.70 (95% confidence interval-CI 0.65–0.75)] and calibration slope of 1.01 (95% CI 0.99–1.03). Compared with the three published consensus-based decision algorithms for ICD use in ARVC (Heart Rhythm Society consensus on arrhythmogenic cardiomyopathy, International Task Force consensus statement on the treatment of ARVC, and American Heart Association guidelines for VA and SCD), the risk calculator performed better with a superior net clinical benefit below risk threshold of 35%. Conclusion: Using a large independent cohort of patients, this study shows that the ARVC risk model provides good prognostic information and outperforms other published decision algorithms for ICD use. These findings support the use of the model to facilitate shared decision making regarding ICD implantation in the primary prevention of SCD in ARVC. Structured Graphical Abstract: Structured Graphical Abstract Validation of the arrhythmogenic right ventricular cardiomyopathy (ARVC) risk calculator in a distinct cohort. AHA, American Heart Association; ECG, electrocardiogram; HRS, Heart Rhythm Society; ICD, implantable cardioverter-defibrillator; ITFC, International Task Force Criteria; NSVT, non-sustained ventricular tachycardia; PVC, premature ventricular complex; VA, ventricular arrhythmia.